β-Blocker Use Not Linked to Reduced Mortality After AMI
No significant difference in mortality for MI patients without HF, LVSD with, without β-blocker use
THURSDAY, June 1, 2017 (HealthDay News) -- β-blocker use is not associated with reduced mortality after acute myocardial infarction (AMI) without heart failure or left ventricular systolic dysfunction (LVSD), according to a study published in the June 6 issue of the Journal of the American College of Cardiology.
Tatendashe B. Dondo, from the University of Leeds in the United Kingdom, and colleagues examined the correlation between β-blocker use and mortality among 179,810 survivors of hospitalization with AMI without heart failure or LVSD (91,895 patients with ST-segment elevation myocardial infarction [STEMI] and 87,915 patients with non-STEMI).
The researchers found that 96.4 and 93.2 percent of patients with STEMI and non-STEMI received β-blockers, respectively. There were deaths in 5.2 percent of the entire cohort. Patients receiving β-blockers had lower unadjusted one-year mortality than non-users (4.9 versus 11.2 percent; P < 0.001). No significant difference was seen in mortality for those with and without β-blocker use after weighting and adjustment (average treatment effect [ATE] coefficient, 0.07; P = 0.827). Similar findings were seen for STEMI (ATE coefficient, 0.30; P = 0.637) and non-STEMI (ATE coefficient, −0.07; P = 0.819).
"Among survivors of hospitalization with AMI who did not have heart failure or LVSD as recorded in the hospital, the use of β-blockers was not associated with a lower risk of death at any time point up to one year," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.